Press release
Clostridium difficile Infections Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Clostridium difficile Infections Disease Pipeline Drugs
Clostridium difficile is a bacterium which infects the bowel and caused diarrhea. This infection is most commonly seen in people who were recently been treated with antibiotics and it can be spread easily to others. Clostridium difficile is also called as C. difficile or C.diff. C.diff infections may cause serious bowel problems. Symptoms of C.diff infections includes watery diarrhea, painful cramps in tummy, dehydration, dry mouth, head ache, loss of weight and appetite etc.
C.diff can be diagnosed by enzyme immunoassay, polymerase chain reaction, GDH or EIA. Treatment for Clostridium difficile infection includes antibiotics course.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/clostridium-difficile-infectionsdisease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx
Segmentation:
By Trial Phase, Clostridium difficile Infections pipeline drugs are segmented as:
• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3
• Phase 4
By Company, Clostridium difficile Infections pipeline drugs are segmented as:
• Synthetic Biologics
• Da Volterra
• Pfizer Inc.
• Valneva SE
• Seres Therapeutics
• Summit Therapeutics
• Rebiotix Inc.
• CRESTOVO
• Merck
• XBiotech
• Others
By Drugs, Clostridium difficile Infections pipeline drugs are segmented as:
• Vancomycin
• Fidaxomicin
• Metronidazole
• Ridinilazole
• Cadazolid
• Bezlotoxumab
• Others
By Type of Condition Clostridium difficile Infections pipeline drugs are segmented as:
• Systemic JIA
• Oligoarthritis
• Polyarticular arthritis, rheumatoid factor negative/ rheumatoid factor positive
• Psoriatic arthritis
• Enthesitis-related arthritis
• Undifferentiated arthritis
By Route of Administration, Clostridium difficile Infections pipeline drugs are segmented as:
• Oral
• Parenteral
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/clostridium-difficile-infectionsdisease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu
Space Analysis:
• In July 2016, Valneva SE completed Phase II study for its prophylactic vaccine candidate VLA84 targeting primary prevention of difficile infection (CDI). The study met its primary endpoint in terms of identifying the dose/formulation with the highest seroconversion rate against both toxins A and B and confirmed the favorable safety profile observed in Phase
• In June 2017, Seres Therapeutics, Inc. initiated Phase 3 clinical study of its SER-109 (ECOSPOR III) in patients with multiply recurrent difficile infection and also commenced Phase 1b clinical trial evaluating SER-262 in patients with primary Clostridium difficile infection (CDI).
• On May 11, 2017 The U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation for SYN-004 (ribaxamase) of Synthetic Biologics for the prevention of Clostridium difficile infection.
• In October 2015, RBX2660 of Rebiotix was grated orphan drug status and fast track designation from U.S.FDA for its potential to prevent recurrent C. diff. infection.
Report Description:
Clostridium difficile Infections Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Clostridium difficile Infections treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Clostridium difficile Infections disease pipeline drugs development. This report studies the dynamics of the Clostridium difficile Infections Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Clostridium difficile Infections disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/clostridium-difficile-infectionsdisease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3
Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on the each drug candidates in the clinical trial phases
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/clostridium-difficile-infectionsdisease-pipeline-drugs-assessment/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Clostridium difficile Infections Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 here
News-ID: 1037103 • Views: …
More Releases from Precision Business Insights
Biochar Market Growth Is Attributed To The Increased Production Of Biochar Throu …
According to Precision Business Insights (PBI), the latest report biochar market was valued at USD 243.8 million in 2022, growing at a 12.6% CAGR during the forecast period 2023 to 2029. The rising demand for organic and eco-friendly products drives the biochar market. Utilizing biochar corresponds with organic farming methods, improving market prospects. Furthermore, biochar is a potential material for water treatment and remediation because of its capacity to absorb…
Vapor Recovery Units Market Growth Is Attributed To The Increased Adoption Of Me …
According to Precision Business Insights (PBI), latest report vapor recovery units market was valued at USD 923.7 million in 2022 and is poised to grow at a CAGR of 4.2% during the forecast period 2023 to 2029. The adoption of stringent environmental regulations by governments and international bodies to reduce air pollution and greenhouse gas emissions in various countries drives the demand for the vapor recovery unit's market. Furthermore, the…
Pyrite Market Growth Is Attributed To The Increased Demand In Jewelry Industry
According to Precision Business Insights (PBI), latest report pyrite market is growing at 4.9% CAGR during the forecast period 2023 to 2029. The increased application of pyrite in the manufacturing of sulfuric acid drives the pyrite market. The increase of prices of gold has led to increased demand for imitation jewelry which is anticipated to propel the pyrite market growth. Furthermore, the demand for sulphuric acid in a variety of…
Industrial Boilers Market Growth Is Attributed To The Increased Use In Power Gen …
According to Precision Business Insights (PBI), the latest report industrial boilers market size was valued at USD 15,261.8 million in 2022 and is poised to grow at a 3.1% CAGR during the forecast period 2023 to 2029. The adoption of stringent environmental regulations to maintain emission standards and carbon reduction in several countries drives the industrial boilers market. Furthermore, the advancement in boiler technology, such as better combustion systems, greater…
More Releases for Clostridium
Clostridium Difficile Diagnostics and Treatment Market – Insights
Clostridium difficile is a disease caused by bacteria. Symptoms of the disease includes diarrhea, nausea, colon inflammation, and others. Clostridium difficile infection affects older adults, and according to Centers for Disease Control and Prevention (CDC), 2015, clostridium difficile infection is the most common healthcare-associated infection. Furthermore, frequent use of antibiotic medication is also responsible for clostridium difficile infection, as antibiotics kill normal flora (good bacteria) and allow for multiplication of…
Clostridium Difficile Diagnostics and Treatment Market – Insights
Clostridium difficile is a disease caused by bacteria. Symptoms of the disease includes diarrhea, nausea, colon inflammation, and others. Clostridium difficile infection affects older adults, and according to Centers for Disease Control and Prevention (CDC), 2015, clostridium difficile infection is the most common healthcare-associated infection. Furthermore, frequent use of antibiotic medication is also responsible for clostridium difficile infection, as antibiotics kill normal flora (good bacteria) and allow for multiplication of…
The Global Clostridium Difficile Infection Treatment Market Driver
Clostridium difficile, which produces gram-positive bacterium, is an anaerobic toxin that gets transmitted through fecal-oral route. Clostridium difficile infection occurs during antibiotic treatment or can be caused due to healthcare associated infection with clinical manifestation ranging from asymptomatic infection to watery diarrhea or serious intestinal condition such as colitis and colonic perforation. This infection can be diagnosed by enzyme immunoassays for toxins or Clostridium difficile glutamate dehydrogenase (GDH) and nucleic…
Clostridium difficile Infections (Clostridium difficile Associated Disease)Marke …
To Understand the pharmaceutical Industry Status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline Review, H2 2017” to its vast database. This study offers data about the prime regions operating in the pharmaceutical sector, along with their production, consumption, revenue and market share details. Further, the intelligent report also anticipates that the market would grow at a constructive CAGR…
Clostridium difficile Infections (Clostridium difficile Associated Disease)Marke …
To Understand the pharmaceutical Industry Status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline Review, H2 2017” to its vast database. This study offers data about the prime regions operating in the pharmaceutical sector, along with their production, consumption, revenue and market share details. Further, the intelligent report also anticipates that the market would grow at a constructive CAGR…
Clostridium Vaccine Market : Share, Analysis To 2024
The global clostridium vaccine (animal health) market features a largely consolidated competitive landscape, with the top five companies collectively accounting for a share of over 63% of the overall market in 2015, observes a recent report by Transparency Market Research (TMR). These top vendors, namely Zoetis, Inc., Merck & Co., Sanofi-Aventis, Boehringer Ingelheim, and Eli Lilly and Company hold commanding positions owing to their wide geographic presence and a strong…
